Abstract: A bioabsorbable and photocurable composition, a bioabsorbable guided tissue regeneration composition, and a grafting method using same are provided. The bioabsorbable and photocurable composition includes a photosensitizer and collagen, and is applied onto an in vivo graft site filled with a graft material, so as to cover the graft material while filling an empty space of the graft site, and the photosensitizer is activated by the irradiation of visible light so that the collagen is cross-linked, and the collagen cross-linked by the visible light fills the minute empty space of the graft site and closely binds the graft material to fix the graft material.

Abstract: Disclosed are a peptide having antibacterial, anti-inflammatory, or tissue regeneration ability and use thereof. The peptide includes an amino acid sequence of SEQ ID NO: 1.

Abstract: The present invention relates to a pharmaceutical composition for treating and preventing gingivoperiodontitis or peri-implantitis, comprising, as effective components, sodium ethylenediaminetetra acetate, cetylpyridinium chloride, octyl phenol ethoxylate, and sodium bicarbonate. The composition according to the present invention can effectively eliminate bacteria causing gingivoperiodontitis and peri-implantitis, thereby alleviating inflammation, and furthermore, an interdental brush coated with the composition is convenient to apply to gaps between teeth, dental implants, orthodontic appliances, etc. and thus can be used to treat and prevent gingivoperiodontitis and peri-implantitis conveniently at home.

Abstract: The present invention relates to a peptide for penetrating the blood-brain barrier and use thereof, and more particularly, a peptide for penetrating the blood-brain barrier and a complex in which the peptide is conjugated to a drug of antibody, protein or therapeutic nucleic acid, and use thereof for the treatment or prevention of brain diseases or brain tumors. The peptide for penetrating the blood-brain barrier of the present invention passes through the cell membrane of brain endothelial cells with excellent efficiency, and the peptide-drug complex in which the peptide for penetrating the blood-brain barrier is combined with a drug such as an antibody, a protein or a therapeutic nucleic acid has the advantage of effectively delivering the drug into the brain parenchyma and maximizing the therapeutic effect of brain diseases and brain tumors.

Abstract: The present invention relates to a proteolysis targeting chimera (PROTAC) protein having an intracellular delivery function, and a pharmaceutical composition comprising same. The PROTAC protein according to the present invention has higher solubility than a PROTAC prepared by a conventional method and efficiently degrades intrinsic disease proteins when applied to cells, and thus is effective in the treatment of cancer or inflammatory diseases.

Abstract: The present invention relates to a carrier for delivering oligonucleotides into cells for therapeutic use. To inhibit a target protein or promote expression of a target protein in a cell, a peptide-lipid conjugate is prepared, and a nanoparticle consisting of a peptide-lipid conjugate comprising oligonucleotides and a pharmaceutical composition comprising same are provided. It was confirmed that, by using the nanoparticle consisting of a peptide-lipid conjugate according to the present invention, oligonucleotides were effectively delivered into cells. In addition, by confirming that expression of a cancer-causing protein is reduced by the oligonucleotides and an anticancer effect is exhibited in an animal model in which cancer occurs, the nanoparticle consisting of a peptide-lipid conjugate was found to be effective in the delivery of oligonucleotides.

Abstract: The present invention relates to a peptide for preventing or treating fibrosis, having the effects of preventing or treating fibrosis by having the property of inhibiting the dissociation of TGF-?1 from LCC by binding to an integrin or the property of inhibiting the change from epithelial cells to mesenchymal cells and promoting the change from mesenchymal cells to epithelial cells, and the property of penetrating cells to bind to Smad2 and Smad3, and thus suppresses the phosphorylation thereof. A peptide according to the present invention exhibits better therapeutic effects than Nintedanib, which was commercialized as a therapeutic agent for pulmonary fibrosis, and Liraglutide, which was commercialized as a therapeutic agent for hepatic fibrosis, and thus can be used as an alternative therapeutic agent to these commercially available therapeutic agents or as an agent for combination therapy with these therapeutic agents.

Abstract: The present invention relates to a novel use of a peptide for inhibiting the functions and expressions of multiple disease biomarkers, and more specifically, to a pharmaceutical composition for treating or preventing inflammation, metabolic diseases or fibrotic diseases, the composition comprising, as an active ingredient, any one or more peptide among peptides which are represented by the amino acid sequences of SEQ ID NOs: 1 to 8, and which, for histone deacetylase 5 (HDAC5), GDF15 and ATF3 which are biomarkers associated with inflammation, metabolic diseases or fibrotic diseases, have the functions of inhibiting HDAC5 phosphorylation, inhibiting the expression of the GDF15 protein and inhibiting the expression of the ATF3 protein.

Abstract: The present invention relates to a GRP78-derived peptide for screening highly efficient stem cells and the use thereof, and more particularly, to screening highly efficient stem cells using, as a marker, a GRP78-derived peptide capable of binding to the binding domain of GRP78 protein on the cell surface. According to the present invention, the GRP78-derived peptide comprising only a specific amino acid sequence capable of recognizing highly efficient stem cells, among the amino acid sequence of GRP78, makes it possible to screen only non-senescent young stem cells. In addition, when stem cells are treated with the GRP78-derived peptide or the GRP78-derived peptide is introduced into stem cells, the efficiency of the stem cells can be increased. Thus, the GRP78-derived peptide is useful for the production of stem cell therapy products having excellent efficacy.

Abstract: The present invention relates to: an antibody targeting a mutation of KRAS, which is an intracellular tumor-inducing protein, or a fusion protein in which a cancer-cell-penetrating peptide is connected, by means of a gene expression method or a chemical bonding method, to a single strand variable fragment of the antibody; and a tumor treatment use thereof. The fusion protein thus produced has the benefit of maximizing the anti-tumor or anti-cancer effect of the antibody targeting an intracellular tumor-inducing protein or a tumor-inducing mutant protein, or the single strand variable fragment of the antibody, by effectively invading a tumor cell.

Abstract: The present invention relates to a BMP-9 variant and a derivative thereof. The variant stimulates endothelial cell-specific signaling, but does not stimulate ectopic ossification-related signaling, as compared to wild-type BMP-9, and thus has the effects of enhancing therapeutic effects on various diseases, including tumors, cardiovascular disease, fibrotic diseases, inflammatory diseases, metabolic diseases, and autoimmune diseases, and reducing side effects.

Abstract: The present invention relates to a peptide for treating inflammation and wounds and, more specifically, to use of a peptide for treating inflammation and wounds, wherein the peptide binds to collagen type VII exposed by damage to tissue and recognizes collagen type VII as an antigen, thereby inhibiting the induction of an immune response, and thus having a function of inhibiting inflammation caused by an autoimmune response, and has the function of promoting wound healing by promoting cell proliferation and migration to a wound site in the damaged tissue. The peptide according to the present invention has the binding ability to collagen type VII, and thus inhibits an immune response caused by collagen type VII, thereby inhibiting inflammation caused by an autoimmune response.

Abstract: The present invention pertains to: a peptide having ATF3-binding ability and represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 4; a fused peptide in which a cell-permeable peptide is bound to the peptide having ATF3-binding ability; and a use of the peptides for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases. According to the present invention, a novel peptide having the ability to bind to ATF3, which is a protein serving as a biomarker and an important factor in the occurrence of various inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases, is provided to thereby regulate the intracellular concentration of ATF3, and can thus be used for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases.

Abstract: Disclosed are a bifunctional peptide having the capability to reduce inflammation and the capability to facilitate differentiation of stem cells into chondrocytes and the use thereof. Advantageously, the bifunctional peptide is useful for the prevention or treatment of arthritis accompanied by inflammation and damage of cartilage tissue due to excellent effects of reducing inflammation and facilitating differentiation of stem cells into chondrocytes, can be easily applied to various surgical regenerative treatments including orthopedic treatments, and can shorten the treatment period.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating bone diseases comprising a fusion peptide in which a bone tissue-selective peptide bound to parathyroid hormone (PTH) or a fragment thereof. More particularly, the present invention relates to a pharmaceutical composition and biomaterial for preventing or treating bone diseases comprising a fusion peptide in which a bone tissue-selective peptide represented by an amino acid sequence of SEQ ID NO. 3 bound to parathyroid hormone (PTH) or a fragment thereof represented by an amino acid sequence of SEQ ID NO. 4 or 5. The fusion peptide can improve effects of PTH by selectively binding to bone tissue and can reduce administration frequency by increasing the half-life. The fusion peptide can be used as a subcutaneous or intravenous injection-type pharmaceutical composition for treating osteoporosis and fracture, and can be used in combination with a medical device for tissue recovery to increase formation of bone tissue.

Abstract: The present invention pertains to: a peptide having ATF3-binding ability and represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 4; a fused peptide in which a cell-permeable peptide is bound to the peptide having ATF3-binding ability; and a use of the peptides for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases. According to the present invention, a novel peptide having the ability to bind to ATF3, which is a protein serving as a biomarker and an important factor in the occurrence of various inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases, is provided to thereby regulate the intracellular concentration of ATF3, and can thus be used for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases.

Abstract: The present invention relates to a novel use of a peptide for inhibiting the functions and expressions of multiple disease biomarkers, and more specifically, to a pharmaceutical composition for treating or preventing inflammation, metabolic diseases or fibrotic diseases, the composition comprising, as an active ingredient, any one or more peptide among peptides which are represented by the amino acid sequences of SEQ ID NOs: 1 to 8, and which, for histone deacetylase 5 (HDAC5), GDF15 and ATF3 which are biomarkers associated with inflammation, metabolic diseases or fibrotic diseases, have the functions of inhibiting HDAC5 phosphorylation, inhibiting the expression of the GDF15 protein and inhibiting the expression of the ATF3 protein.

Abstract: The present invention relates to a pharmaceutical composition for treating and preventing gingivoperiodontitis or peri-implantitis, comprising, as effective components, sodium ethylenediaminetetra acetate, cetylpyridinium chloride, octyl phenol ethoxylate, and sodium bicarbonate. The composition according to the present invention can effectively eliminate bacteria causing gingivoperiodontitis and peri-implantitis, thereby alleviating inflammation, and furthermore, an interdental brush coated with the composition is convenient to apply to gaps between teeth, dental implants, orthodontic appliances, etc. and thus can be used to treat and prevent gingivoperiodontitis and peri-implantitis conveniently at home.

Abstract: The present invention relates to a peptide for inhibiting bone resorption and, more specifically, to a peptide for inhibiting bone destruction by inhibiting the differentiation and activity of osteoclasts. According to the present invention, a peptide for inhibiting bone resorption can inhibit bone destruction by inhibiting the differentiation and activity of osteoclasts, and thus can be used as a therapeutic agent for various bone diseases caused by an excessive increase in the activity of osteoclasts.

Abstract: The present invention relates to an integrated biomaterial for bone tissue regeneration and a method of preparing the same, and more particularly to an integrated biomaterial for bone tissue regeneration, which includes a lower structure consisting of an extracellular matrix protein and a bone mineral and an upper layer consisting of an extracellular matrix protein. In the integrated biomaterial for bone tissue regeneration according to the present invention, the lower structure consisting of an extracellular matrix protein and a bone mineral component realizes a natural bone tissue environment, and thus facilitates the regeneration of new bone, and particularly, the upper layer consisting of an extracellular matrix protein is placed thereon at an appropriate ratio, and thus not only prevents the infiltration of epithelial tissue or connective tissue but also maximizes bone tissue regeneration capability.